ArticleBMJ open2020

Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials.

Qiancheng Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.